IndustryCompany release

Gyre Therapeutics details degrader pipeline and China revenue outlook in November 2026 presentation

🇺🇸 Gyre Therapeutics, Inc. (GYRE) · Thu 05 Nov 2026

The San Diego company projects FY26 China revenue of $100.5M-$111M, a possible 2027 China launch for F351 and a mid-2027 Phase 1 start for CG923308.

Gyre Therapeutics, based in San Diego, has published a corporate presentation dated November 2026 that sets out its targeted protein degrader and degrader-antibody conjugate platform alongside its existing China commercial business.

The company said that business, led by ETUARY (pirfenidone) for idiopathic pulmonary fibrosis, is expected to generate FY26 revenue of $100.5M-$111M. It also said F351 could launch in China in the first half of 2027.

On the degrader side, Gyre highlighted CG923308, a CDK2/Cyclin E degrader aimed at breast cancer resistant to CDK4/6 inhibitors and at other solid tumours. The company expects to submit an IND in the US and/or China and to begin Phase 1 around mid-2027.

The full presentation text was not available for this report, so further details on trial design, funding or regulatory interactions are not covered. The timelines are company expectations, not regulatory approvals or agreed milestones.

What it means for your team

  • Regulatory teams tracking China-based development should note that the CG923308 IND may be filed in the US, China or both, with the route still open.
  • Market-access teams in China should watch for an F351 launch in the first half of 2027, as stated by the company.
  • The FY26 revenue range and development dates are company guidance and may change.

Company's press release (SEC filing): Gyre Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Gyre Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →